Alcobra Ltd. (NASDAQ:ADHD) lost $1.09 (13%) to $7.30 on Wednesday after it said metadoxine ER missed the primary endpoint in a Phase II trial to treat Fragile X syndrome. The study showed no statistically significant …

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) lost $1.74 (12%) to $13.28 on Friday on news its TKM-Ebola-Guinea was unlikely to show a therapeutic effect in the Phase II RAPIDE trial to treat Ebola virus infection. As a …

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) gained $15.06 (12%) to an all-time high closing price of $138.66 on Thursday after it reported results post-market Wednesday from a Phase II study of vosoritide (BMN 111) to …

Radius Health Inc. (NASDAQ:RDUS) gained $7.91 (15%) to $59.64 after it released six-month top-line data from the ACTIVExtend extension study and from a combined analysis of ACTIVExtend and the Phase III ACTIVE study of …

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $6.64 (50%) to $19.91 on Tuesday after it said FDA will allow the company to change the primary endpoint of the Phase III Rocket 2 trial of glaucoma treatment Rhopressa (…

Avalanche Biotechnologies Inc. (NASDAQ:AAVL) lost $21.83 (56%) to $17.05 on Tuesday, touching a 52-week low of $17.01 after it released top-line data from a Phase IIa study of its AVA-101 gene therapy to treat wet age-…

UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in February. UCB plans to…

bluebird bio Inc. (NASDAQ:BLUE) said a sickle cell disease (SCD) patient treated with LentiGlobin BB305 gene therapy has remained transfusion independent for three months since receiving his last transfusion 88 days …

Data presented at the European Hematology Association meeting showed that melflufen from Oncopeptides AB (Stockholm, Sweden) could have similar efficacy to other clinical candidates in heavily pre-treated multiple …

Aimmune Therapeutics Inc. (Brisbane, Calif.) reported results from the Phase II ARC001 study of AR101 to treat peanut allergy.The company said that all 23 patients who completed treatment with AR101 met the primary …